27 research outputs found
Metabolic properties of irisin in health and in diabetes mellitus
Irisin is a polypeptide hormone of muscle tissue (myokine), the synthesis and secretion of which increase against the background of physical exertion, which plays a significant role in the metabolism of fat, muscle and bone tissues. It is known that irisin promotes the transformation of white adipose tissue into brown adipose tissue. It has also been experimentally proven that the introduction of irisin contributed to an increase in bone mass and the prevention of osteoporosis and muscular atrophy. There are works indicating a positive effect of irisin in the functioning of bone, fat and muscle tissues in humans. Diabetes mellitus (DM) is an independent risk factor for osteoporotic fractures and the development of specific diabetic myopathy, at the cellular level similar to the aging of muscle tissue, and type 2 diabetes is also associated with the presence of obesity. Thus, it is of particular interest to study the effect of irisin on the state of bone, muscle and adipose tissues and glucose homeostasis in patients with diabetes. This literature review highlights the biological functions of irisin in healthy people and patients with DM
Π£ΡΠΎΠ²Π΅Π½Ρ 25(ΠΠ)D Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ COVID-19
Recently, vitamin D deficiency is considered as a risk factor for the incidence and severity of new coronavirus infection. The aim of this work was to evaluate the vitamin D level of patients with COVID-19 hospitalized with communityacquired pneumonia and compare the value of 25(OH)D in blood serum with the clinical manifestations of the disease. Results. Included are 80 patients aged 18 to 94 years (mean age 53,2 Β± 15,7 years), 43 (53,8%) men; with severe course β in 25 (31,3%) patients (12 males), and moderate β in 55 people (68,7%) (31 males). Half of the severely ill patients were obese, and among the deceased patients, the number of obese people was 61,5%, which was significantly higher than the discharged ones β 14,9% (p<0,001). Diabetes mellitus and cardiovascular diseases occurred with the same frequency, regardless of the severity of the disease. Analysis of the outcomes of coronavirus infection in these patients showed mortality in 52,0% of cases in severe patients. Serum 25(OH)D level ranged from 3,0 to 88,8 ng / ml (16,7 Β± 12,7 ng / ml). It was found that in patients with severe course, the level of 25(OH)D blood was significantly lower (11.9 Β± 6.4 ng / ml) and vitamin D deficiency was more common than in patients with moderate to severe course of the disease (18,5 Β± 14,0 ng / ml, p = 0,027). The same pattern was revealed in patients with a fatal outcome, where the level of 25(OH)D was 10,8 Β± 6,1 ng / ml, compared with this indicator in patients discharged from the hospital (17,8 Β± 13,4 ng / ml) (p = 0,02). Conclusions. Vitamin D deficiency and obesity have been found to increase the risk of severe course and death of coronavirus infection.Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π΅ Π²ΡΠ΅ΠΌΡ Π΄Π΅ΡΠΈΡΠΈΡ ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΠΊ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡ ΡΠΈΡΠΊΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½Π½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½ΠΎΠΌ D Π±ΠΎΠ»ΡΠ½ΡΡ
COVID-19, Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ Π²Π½Π΅Π±ΠΎΠ»ΡΠ½ΠΈΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠ΅ΠΉ ΠΈ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΡΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ 25(ΠΠ)D Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 80 Π±ΠΎΠ»ΡΠ½ΡΡ
Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 18 Π΄ΠΎ 94 Π»Π΅Ρ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 53,2Β±15,7 Π»Π΅Ρ), 43 (53,8%) ΠΌΡΠΆΡΠΈΠ½; Ρ ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Ρ 25 (31,3%) Π±ΠΎΠ»ΡΠ½ΡΡ
(12 ΠΌΡΠΆΡΠΈΠ½), ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠΌ Ρ 55 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ (68,7%) (31 ΠΌΡΠΆΡΠΈΠ½Π°). ΠΠΎΠ»ΠΎΠ²ΠΈΠ½Π° Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠ΅Π»ΠΈ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅, Π° ΡΡΠ΅Π΄ΠΈ ΡΠΌΠ΅ΡΡΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π»ΠΈΡ Ρ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 61,5%, ΡΡΠΎ Π±ΡΠ»ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Ρ Π²ΡΠΏΠΈΡΠ°Π½Π½ΡΡ
, β 14,9% (p<0,001). Π‘Π°Ρ
Π°ΡΠ½ΡΠΉ Π΄ΠΈΠ°Π±Π΅Ρ ΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Ρ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎΠΉ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ½Π°Π»ΠΈΠ· ΠΈΡΡ
ΠΎΠ΄ΠΎΠ² ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ Π΄Π°Π½Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°Π» Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ Π² 52,0% ΡΠ»ΡΡΠ°Π΅Π² ΠΏΡΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ. Π£ΡΠΎΠ²Π΅Π½Ρ 25(ΠΠ)D Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΡΡ Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΎΡ 3,0 Π΄ΠΎ 88,8 Π½Π³/ΠΌΠ» (16,7Β±12,7 Π½Π³/ΠΌΠ»). Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π΅Π½Ρ 25(ΠΠ)D ΠΊΡΠΎΠ²ΠΈ Π±ΡΠ» Π·Π½Π°ΡΠΈΠΌΠΎ Π½ΠΈΠΆΠ΅ (11,9Β±6,4 Π½Π³/ΠΌΠ»), ΠΈ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΡΠ΅ΡΠ°Π»ΡΡ ΡΠ°ΡΠ΅, ΡΠ΅ΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (18,5Β±14,0 Π½Π³/ΠΌΠ», Ρ=0,027). Π’Π°ΠΊΠ°Ρ ΠΆΠ΅ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΡ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π»Π΅ΡΠ°Π»ΡΠ½ΡΠΌ ΠΈΡΡ
ΠΎΠ΄ΠΎΠΌ, Π³Π΄Π΅ ΡΡΠΎΠ²Π΅Π½Ρ 25(ΠΠ)D Π±ΡΠ» 10,8Β±6,1 Π½Π³/ΠΌΠ», ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄Π°Π½Π½ΡΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, Π²ΡΠΏΠΈΡΠ°Π½Π½ΡΡ
ΠΈΠ· ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ° (17,8Β±13,4 Π½Π³/ΠΌΠ») (Ρ=0,02). ΠΡΠ²ΠΎΠ΄Ρ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΈ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ² ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause
BACKGROUND: Diabetes mellitus (DM) is an independent risk factor for low-traumatic fractures. On the other hand, hypoglycemic drugs can have both positive and negative effects on bone remodeling.THE AIM: Π’o investigate bone metabolism parameters during surgical menopause and experimental DM under the treatment with glucagon-like peptide receptor agonist type 1 (arGLP-1) liraglutide (LIRA) and sodium-glucose cotransporter type 2 inhibitor (iSGLT-2) canagliflozin (CANA).MATERIALS AND METHODS: Female Wistar rats have been subjected to bilateral ovariectomy at the beginning of the experiment. Diabetes mellitus (DM) was modelled using a high-fat diet and streptozotocin+nicotinamide. Four weeks after the following groups were formed: βOE+DMβ (females after ovariectomy with DM and without any therapy, n=4) Β«OE+DM+CANAΒ» (females after ovariectomy with DM under treatment with CANA, n=4), Β«OE+DM+LIRAΒ» (females after ovariectomy with DM under treatment LIRA, n=5). The treatment or observation period were continuing for 8 weeks. Calcium, phosphorus and bone turnover markers (fibroblast growth factor-23 (FGF-23), osteocalcin, sclerostin, osteoprotegerin (OPG), nuclear factor-kappa-B receptor activator ligand (RANKL), were measured in the end of experiment. Bone histomorphometry was performed after euthanasia.RESULTS: Treatment with both CANA and LIRA did not significantly affect the phosphorus-calcium metabolism, sclerostin and osteocalcin concentrations. At the same time, the level of OPG was the highest in Β«OE+DM ββ group (9.1 [7.81; 10.045] pmol/l). The differences were significant compared with Β«OE+DM+CANAββ (2, 33 [1.84; 5.84] pmol/l, p = 0.003) and Β«OE+DM+LIRAΒ» (1.7 [1; 2] pmol/l, p = 0.003) groups. There were no differences in OPG levels between animals treated with different drugs. Similarly, the OPG/RANKL ratio was similarly reduced with both types of treatment. In βOE+DM+CANAββ group the bone trabeculae number ofΒ Β the femur epiphysis (p=0.042) were decreased in comparison to Β«OE+DMΒ» group. LIRA did not change the histoarchitectonic parameters.CONCLUSION: Bone metabolism markers did not differ when using as canagliflozin as liraglutide. Besides, canagliflosin can lead to the activation of bone resorption, which is expressed in the femur epiphyseal trabeculae number decreasing
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
Background: Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having optimal cardioprotective properties. A comparative study of the various sodium-glucose co-transporter inhibitors representativesβ protective effects in experimental MI was not carried out within the framework of one study.Aim: To evaluate the influence of empagliflozin (EMPA) and canagliflozin (CANA), in comparison with sitagliptin (SITA), on hemodynamic parameters and myocardial damage area in rats with diabetes type 2 model in experimental MI.Materials and methods: Type 2 DM was modelled in Wistar rats by means of 4-week high-fat diet followed by nicotinamide 230 mg/kg and streptozotocin 60 mg/kg administration. 4 weeks after DM induction the following groups were made: Β«DM+SITAΒ» β treatment with SITA 50 mg/kg, Β«DM+EMPAΒ» β treatment with EMPA 2 mg/kg, Β«DM+CANAΒ» β treatment with CANA 25 mg/kg per os once daily for 8 weeks. Animals in Β«DMΒ» group remained untreated for the following 8 weeks. Rats in control group were fed with standard chow. 16 weeks after the experiment beginning transient global myocardial ischemia was modelled in all rats. Hemodynamic parameters and myocardium necrosis area were evaluated.Results: The necrosis area was larger in Β«DMΒ» group, than in control one (p=0.018). Infarction size in Β«DM+SITAΒ» did not differ from that in Β«DMΒ» group (62.92(41.29;75.84) and 57.26(45.51;70.08)%, Ρ=0.554). Necrosis area in Β«DM+EMPAΒ» and Β«DM+CANAΒ» groups was smaller than in Β«DMΒ» group (37.90(20.76;54.66)%, 46.15(29.77;50.55) vs 57.26(45.51;70.08)%, Ρ=0.008 and Ρ=0.009, respectively). Necrosis size did not differ between Β«DM+EMPAΒ» and Β«DM+CANAΒ» groups (p=0.630). Ischemic contracture in Β«DM+CANAΒ» group was less prominent than under the use of all other glucose-lowering drugs. We observed increase of coronary blood flow in Β«DM+EMPAΒ» group, in comparison with Β«DMΒ», Β«DM+CANAΒ» and Β«DM+SITAΒ» groups.Conclusions: SITA does not have cardioprotective effect in ischemia-reperfusion injury in diabetic rats. EMPA and CANA have similarly prominent infarct-limiting properties. EMPA is able to increase coronary blood flow, whereas cardioprotective action of CANA is associated with ischemic contracture diminishing
Π‘Π²ΡΠ·Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Ρ ΠΆΠ΅Π½ΡΠΈΠ½
Introduction. The development of metabolic syndrome (MS) in patients with abdominal obesity (AO) may be associated with a low level of the adiponectin (AN) - protective adipocytokine. AN circulates in the blood in various molecular forms.The high molecular weight AN is assumed to have greater metabolic activity. It is currently not clear what level of high molecular weight adiponectin (HMWA) in women with AO is associated with MS and its components.The objective was to study the role of high molecular weight adiponectin in the development of metabolic syndrome in women with abdominal obesity.Methods and materials. 302 women with AO and 161 women without AO were examined. MS was diagnosed in 62.3 % of patients.Results. The concentration of total adiponectin (TAN) and HMAN in the blood serum in women with MS was lower than in patients without MS (p<0.05). According to logistic regression analysis, the most significant factors influencing the risk of MS were low concentration of HMAN in the blood, age, and body mass index (p <0.05).Conclusions. It was found that women with AO and HMAN concentration of less than 1.96 ΞΌg/ml in the blood had an increased risk of metabolic syndrome.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°Π·Π²ΠΈΡΠΈΠ΅ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° (ΠΠ‘) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ (ΠΠ) ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π² ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π°Π΄ΠΈΠΏΠΎΡΠΈΡΠΎΠΊΠΈΠ½Π° β Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° (ΠΠ), ΠΊΠΎΡΠΎΡΡΠΉ ΡΠΈΡΠΊΡΠ»ΠΈΡΡΠ΅Ρ Π² ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ΅ Π² Π²ΠΈΠ΄Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΡΠΎΡΠΌ. Π‘ΡΠΈΡΠ°Π΅ΡΡΡ, ΡΡΠΎ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ ΡΠΎΡΠΌΠ° ΠΠ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅ ΡΡΠ½ΠΎ, ΠΊΠ°ΠΊΠΎΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° (ΠΠΠΠ) Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΠ Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ Ρ ΠΠ‘ ΠΈ Π΅Π³ΠΎ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΠΌΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°ΠΌΠΈ.Π¦Π΅Π»Ρ β ΠΈΠ·ΡΡΠΈΡΡ ΡΠΎΠ»Ρ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ.ΠΠ΅ΡΠΎΠ΄Ρ ΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 302 ΠΆΠ΅Π½ΡΠΈΠ½Ρ Ρ ΠΠ ΠΈ 161 ΠΆΠ΅Π½ΡΠΈΠ½Π° Π±Π΅Π· ΠΠ. ΠΠ‘ Π±ΡΠ» Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½ Ρ 62,3 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΎΠ±ΡΠ΅Π³ΠΎ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° (ΠΠΠ) ΠΈ ΠΠΠΠ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΠ‘ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Π±Π΅Π· ΠΠ‘ (Ρ<0,05). ΠΠΎ Π΄Π°Π½Π½ΡΠΌ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ, Π²Π»ΠΈΡΡΡΠΈΠΌΠΈ Π½Π° ΡΠΈΡΠΊ ΠΠ‘, Π±ΡΠ»ΠΈ Π½ΠΈΠ·ΠΊΠ°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΠΠΠ Π² ΠΊΡΠΎΠ²ΠΈ, Π²ΠΎΠ·ΡΠ°ΡΡ ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° (Ρ<0,05).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΠ ΠΏΡΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΠΠΠ ΠΌΠ΅Π½Π΅Π΅ 1,96 ΠΌΠΊΠ³/ΠΌΠ» Π² ΠΊΡΠΎΠ²ΠΈ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ ΡΠΈΡΠΊ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°
ΠΠΠΠΠΠΠΠΠ Π£Π ΠΠΠΠ― ΠΠΠΠΠΠΠΠΠ’ΠΠΠ Π ΠΠΠ’ΠΠΠΠΠΠ§ΠΠ‘ΠΠΠ₯ ΠΠΠΠΠΠΠ’ΠΠΠΠ ΠΠ Π ΠΠΠΠΠ€ΠΠΠΠ¦ΠΠ ΠΠΠ ΠΠΠ ΠΠΠΠΠ Π£ ΠΠΠΠ¬ΠΠ«Π₯ ΠΠΠΠΠΠΠΠΠΠ¬ΠΠ«Π ΠΠΠΠ ΠΠΠΠΠ
The paper studied nutritional habits, physical loads, anthropometric and metabolic perfromances, and revealed the changes required to increase the level of adiponectine under drug-free modalities of treatment of patients suffering from abdominal obesity. A 3-year randomized lifestyle intervention trial was performed in 153 patients with AO, age 30-53 yrs, 74 patients (group 1) performed individual hypocaloric diet balanced in fat intake, 79 patients (group 2) performed diet and individual aerobic exercise All patients received individual recommendations on changing their life style. Dynamics of anthropometric, metabolic parameters, physical capacity and adiponectin level were measured. Relation between low level of adiponectin and some metabolic disorders, and sedentary life were revealed. The rate of improving anthropometric parameters, physical capacity, and nutritionassociated with increasing adiponectin was established.Π ΡΠ°Π±ΠΎΡΠ΅ Π±ΡΠ»ΠΈ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΈΡΠ°Π½ΠΈΡ, ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°Π³ΡΡΠ·ΠΎΠΊ, Π°Π½ΡΡΠΎΠΏΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΈ Π²ΡΡΠ²Π»Π΅Π½Π° ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΡ
Π΄Π»Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° ΠΏΡΠΈ Π½Π΅ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ. ΠΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ 3-Π»Π΅ΡΠ½Π΅Π΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΎΠ±ΡΠ°Π·Π° ΠΆΠΈΠ·Π½ΠΈ Ρ 153 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 30 - 55 Π»Π΅Ρ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π² 2 Π³ΡΡΠΏΠΏΡ Π»Π΅ΡΠ΅Π½ΠΈΡ: Π΄ΠΈΠ΅ΡΠΎΠΉ - 74 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ Π΄ΠΈΠ΅ΡΡ ΠΈ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ - 79 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ. ΠΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ Π±ΡΠ»ΠΈ Π΄Π°Π½Ρ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΠ±ΡΠ°Π·Π° ΠΆΠΈΠ·Π½ΠΈ. Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° Π°Π½ΡΡΠΎΠΏΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
, ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ², ΡΡΠΎΠ²Π½Ρ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° ΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° ΠΏΠΈΡΠ°Π½ΠΈΡ ΠΈ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ. ΠΡΠ»Π° ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠ½ΠΈΠΆΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΠ ΠΈ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΠΌΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΎΠΌ ΠΏΠΈΡΠ°Π½ΠΈΡ ΠΈ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ Π°Π½ΡΡΠΎΠΏΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΊΠ°Π»ΠΎΡΠΈΠΉΠ½ΠΎΡΡΠΈ ΠΈ ΠΆΠΈΡΠ½ΠΎΡΡΠΈ ΠΏΠΈΡΠ°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°Π±ΠΎΡΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ, ΠΏΡΠΈ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΊΠΎΡΠΎΡΡΡ
ΡΡΠΎΠ²Π΅Π½Ρ Π°Π΄ΠΈΠΏΠΎΠ½Π΅ΠΊΡΠΈΠ½Π° ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ
Π’ΡΠΆΠ΅ΡΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ Π°ΡΡΠ΅ΡΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΡΠ΅ΡΠ΄ΡΠ° Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΈ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½Π½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½ΠΎΠΌ D
Introduction. Vitamin D deficiency may be an independent predictor of coronary heart disease (CHD) and the severity of coronary atherosclerosis. The results of studies of the association of various polymorphisms of the vitamin D receptor (VDR) gene with the risk and severity of CHD are contradictory, which necessitates the study of genetic variants of the VDR gene and the characteristics of the clinical course of CHD in the Russian population.The objective was to determine the distribution of genotypes of TaqI, BsmI and ApaI of polymorphic variants of the VDR gene and the level of vitamin D sufficiency in CHD patients with varying severity of CHD, residents of St. Petersburg.Methods and materials. The study included 407 CHD patients and 318 patients without clinical signs of CHD of comparable age (p>0.05). All CHD patients underwent coronary angiography. Typing of the VDR gene variants was performed by polymerase chain reaction and subsequent restriction analysis. Determination of the level of 25(OH)D blood serum was carried out by enzyme immunoassay.Results. Vitamin D deficiency was detected in 82 % of CHD patients, the content of 25(OH)D in blood serum was lower in CHD patients who had 2 or more myocardial infarctions (MI) than in those who had one MI (p=0.03). Vitamin D deficiency is associated with a 3.6-fold increased risk of multivessel disease (p=0.01). The presence of the aa genotype and the a allele (ApaI), the bb genotype and the b allele of the VDR gene (BsmI) is associated with an increased risk of CHD and the severity of atherosclerotic lesions of the coronary arteries.Conclusion. Vitamin D deficiency is typical for CHD patients and is associated with the severity of coronary atherosclerosis. The presence of aa genotype and a allele (ApaI polymorphism), bb genotype and b allele of the VDR gene (BsmI polymorphism) is associated with an increased risk of CHD and the severity of atherosclerotic lesions of the coronary arteries. TaqI polymorphism of the VDR gene is not associated with the risk of CHD.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠΌ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ΅ΡΠ΄ΡΠ° (ΠΠΠ‘) ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ²ΡΠ·ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠ² Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D (VDR) Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΈ ΡΡΠΆΠ΅ΡΡΡΡ ΠΠΠ‘ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠΈΠ²Ρ, ΡΡΠΎ ΠΎΠ±ΡΡΠ»Π°Π²Π»ΠΈΠ²Π°Π΅Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½Π° VDR ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠΌ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ΅ΡΠ΄ΡΠ° (ΠΠΠ‘) ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ²ΡΠ·ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠ² Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D (VDR) Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΈ ΡΡΠΆΠ΅ΡΡΡΡ ΠΠΠ‘ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠΈΠ²Ρ, ΡΡΠΎ ΠΎΠ±ΡΡΠ»Π°Π²Π»ΠΈΠ²Π°Π΅Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½Π° VDR ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ.Π¦Π΅Π»Ρ β ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² TaqI, BsmI ΠΈ ApaI ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΈ ΡΡΠΎΠ²Π½Ρ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½Π½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½ΠΎΠΌ D Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ‘ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΡΡΠΆΠ΅ΡΡΡΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ, ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π°.ΠΠ΅ΡΠΎΠ΄Ρ ΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 407 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ‘ ΠΈ 318 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π±Π΅Π· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΠΠ‘, ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (Ρ>0,05). ΠΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΠΠ‘ Π±ΡΠ»Π° Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΠΊΠΎΡΠΎΠ½Π°ΡΠΎΠ³ΡΠ°ΡΠΈΡ. Π’ΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½Π° VDR ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ 25(OH)D ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ 82 % Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ‘ Π²ΡΡΠ²Π»Π΅Π½ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D, ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ 25(ΠΠ)D ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ Π±ΡΠ»ΠΎ Π½ΠΈΠΆΠ΅ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ‘, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
Π΄Π²Π° ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° (ΠΠ), ΡΠ΅ΠΌ Ρ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΎΠ΄ΠΈΠ½ ΠΠ (Ρ=0,03). ΠΠ΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΡΠΊΠ° ΠΌΠ½ΠΎΠ³ΠΎΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π² 3,6 ΡΠ°Π·Π° (Ρ=0,01). ΠΠ°Π»ΠΈΡΠΈΠ΅ aaΒΠ³Π΅Π½ΠΎΡΠΈΠΏΠ° ΠΈ Π°-Π°Π»Π»Π΅Π»Ρ (ΠΡΠ°I), bb-Π³Π΅Π½ΠΎΡΠΈΠΏa ΠΈ b-Π°Π»Π»Π΅Π»Ρ Π³Π΅Π½Π° VDR (BsmI) Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΡΠΊΠ° ΠΠΠ‘ ΠΈ Ρ ΡΡΠΆΠ΅ΡΡΡΡ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ΅Π½ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ‘ ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ Ρ ΡΡΠΆΠ΅ΡΡΡΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°. ΠΠ°Π»ΠΈΡΠΈΠ΅ aa-Π³Π΅Π½ΠΎΡΠΈΠΏΠ° ΠΈ Π°-Π°Π»Π»Π΅Π»Ρ (ΠΡΠ°I-ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ), bb-Π³Π΅Π½ΠΎΡΠΈΠΏa ΠΈ b-Π°Π»Π»Π΅Π»Ρ Π³Π΅Π½Π° VDR (BsmI-ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ) Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΡΠΊΠ° ΠΠΠ‘ ΠΈ Ρ ΡΡΠΆΠ΅ΡΡΡΡ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ. TaqI-ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ Π³Π΅Π½Π° VDR Π½Π΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΠΠ‘
ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠ΅Π»Π»Π΅ΠΊΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π΄Π»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°
Aim. To create algorithm and risk calculator for predicting the lethal outcome in patients with COVID-19.Materials and methods. Based on machine learning approach mortality risk calculator was developed in Almazov National Medical Research Centre using data of the hospitalised patients with an established diagnosis of COVID-19 (n=4071).Results. This mathematical model, which includes 11 significant features, has been proposed for estimation of fatal outcomes in the Clinical Infectious Hospital named after S.P. Botkin. Some key features were not assessed in most hospitals according to accepted standards of care for COVID-19. So systematic analysis of factors affecting the course of disease in patients (n=2876) were conducted and Β«ureaΒ» and Β«total proteinΒ» were replaced with Β«sexΒ» and Β«BMIΒ». Modified algorithm demonstrated high sensitivity and specificity. Conclusion. This calculator is able to predict hospitalisation outcome with high accuracy in patients infected with different strains of SARS-CoV-2. This decision support system may be used for risk stratification and following correct patients routing.Π¦Π΅Π»Ρ: ΡΠΎΠ·Π΄Π°ΡΡ Π°Π»Π³ΠΎΡΠΈΡΠΌ ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΊΠ°Π»ΡΠΊΡΠ»ΡΡΠΎΡ ΡΠ°ΡΡΠ΅ΡΠ° ΡΠΈΡΠΊΠ° Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡ
ΠΎΠ΄Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
COVID-19 ΡΠΎ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ, Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Β Π² ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΉ ΡΡΠ°ΡΠΈΠΎΠ½Π°Ρ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ COVID-19, Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π² ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΉ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ ΠΈΠΌ. Π.Π. ΠΠ»ΠΌΠ°Π·ΠΎΠ²Π° Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 05.2020 Π³. ΠΏΠΎ 08.2021 Π³. (n=4071), ΡΠΎΠ·Π΄Π°Π½ ΠΊΠ°Π»ΡΠΊΡΠ»ΡΡΠΎΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΡΠΊΠ° Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡ
ΠΎΠ΄Π° Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΌΠ°ΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ Π°Π»Π³ΠΎΡΠΈΡΠΌ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΠΉ 11 Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ², Π±ΡΠ» ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° ΡΠΈΡΠΊΠ° Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡ
ΠΎΠ΄Π° Π² ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠΉ Π±ΠΎΠ»ΡΠ½ΠΈΡΠ΅ ΠΈΠΌ. Π‘.Π. ΠΠΎΡΠΊΠΈΠ½Π° Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 05.09.2022 Π³. ΠΏΠΎ 01.03.2023 Π³. Π£ΡΠΈΡΡΠ²Π°Ρ, ΡΡΠΎ ΡΠ°ΠΊΡΠΎΡΡ Β«ΠΠΎΡСвина» и Β«ΠΠ±ΡΠΈΠΉ Π±Π΅Π»ΠΎΠΊΒ» Π½Π΅ Π²Ρ
ΠΎΠ΄ΠΈΠ»ΠΈ Π² ΡΡΠ°Π½Π΄Π°ΡΡ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
, Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π½ΠΎΠ²ΡΡ
Π΄ΠΎΡΡΡΠΏΠ½ΡΡ
Π΄Π»Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠΎΠ² ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠ°ΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ (n=2876) Π±ΡΠ»ΠΈ Π²ΡΠ±ΡΠ°Π½Ρ ΡΠ°ΠΊΡΠΎΡΡ Β«ΠΠΎΠ»Β» ΠΈ Β«ΠΠΠ’Β». Π’Π°ΠΊΠ°Ρ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»Π° Π°Π΄Π°ΠΏΡΠΈΡΠΎΠ²Π°ΡΡΒ Π½Π°ΡΡΠΎΡΡΠΈΠΉΒ Π°Π»Π³ΠΎΡΠΈΡΠΌ ΠΊ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅, ΡΠΎΡ
ΡΠ°Π½ΠΈΠ² Π²ΡΡΠΎΠΊΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ΄Π΅Π»ΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: Π΄Π°Π½Π½ΡΠΉ ΠΊΠ°Π»ΡΠΊΡΠ»ΡΡΠΎΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Ρ Π²ΡΡΠΎΠΊΠΎΠΉ Π΄ΠΎΠ»Π΅ΠΉ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΠΈΡΡ
ΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΡΠΈΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ°ΠΌΠΌΠ°Ρ
Π²ΠΈΡΡΡΠ° SARS-CoV-2. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ°ΠΊΠΎΠ³ΠΎ Π°Π»Π³ΠΎΡΠΈΡΠΌΠ° ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΠΏΡΠΈΠ½ΡΡΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΌΠΎΠΆΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½Ρ ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΡΠΊΠ° ΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠ½ΠΎΠΉ ΠΌΠ°ΡΡΡΡΡΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΈΠ·Π±ΡΡΠΎΡΠ½ΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ Π½Π° ΡΠΈΡΡΠ΅ΠΌΡ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ
Π ΠΠ‘ΠΠ ΠΠΠΠΠΠΠΠ ΠΠΠΠΠ’ΠΠΠΠ Π ΠΠ‘Π’Π ΠΠ§ΠΠΠΠΠ‘Π’Π¬ ΠΠΠΠΠΠΠ ΠΠΠΠ ΠΠΠ¬ΠΠΠ‘Π’ΠΠ ΠΠ-Π‘ΠΠΠ’ΠΠΠ« Π£ ΠΠΠΠ¬ΠΠ«Π₯ ΠΠΠΠΠΠΠΠΠΠ¬ΠΠ«Π ΠΠΠΠ ΠΠΠΠΠ
We observed 140 patients with abdominal obesity (AO) (IDF, 2005), the residents of St. Petersburg (44.6 Β± 0.6 years). Metabolic syndrome (MS) (IDF, 2005) was diagnosed in 49.2% of patients with AO. The most frequent component of MS in patients with AO was arterial hypertension (AH). The distribution of genotypes and -alleles of the aldosterone-synthase gene in patients with AO and in the comparison group (56 subjects without AO, 41.0 Β± 1.1 years) didn't differ (p> 0.05). Levels of both systolic and diastolic blood pressure (BP) were higher in carriers of -344T allele of aldosterone-synthase gene. Plasma renin activity, plasma aldosterone and glucose levels, anthropometric parameters, serum blood lipids and carbohydrate metabolism indices in obese patients with different genotypes of aldosterone-synthase gene didn't differ. -344T allele of aldosterone-synthase gene in patients with AO is associated with the increased risk of AH.ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 140 Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ (ΠΠ) (IDF, 2005), ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π° (44,6Β±0,6 Π³ΠΎΠ΄Π°). Π£ 49,2 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ Π±ΡΠ» Π²ΡΡΠ²Π»Π΅Π½ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ (ΠΠ‘) (IDF, 2005). Π‘Π°ΠΌΡΠΌ ΡΠ°ΡΡΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ ΠΠ‘ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ Π±ΡΠ»Π° Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ (ΠΠ). Π Π°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΈ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΡ Π°Π»Π»Π΅Π»Π΅ΠΉ Π³Π΅Π½Π° Π°Π»ΡΠ΄ΠΎΡΡΠ΅ΡΠΎΠ½-ΡΠΈΠ½ΡΠ°Π·Ρ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ ΠΈ Π² Π³ΡΡΠΏΠΏΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ (56 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π±Π΅Π· ΠΠ, 41,0Β±1,1 Π³ΠΎΠ΄Π°) Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»ΠΎΡΡ (Ρ>0,05). Π£ΡΠΎΠ²Π½ΠΈ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ (ΠΠ), ΠΊΠ°ΠΊ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΈ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, Π±ΡΠ»ΠΈ Π²ΡΡΠ΅ Ρ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ -344Π’-Π°Π»Π»Π΅-Π»Ρ Π³Π΅Π½Π° Π°Π»ΡΠ΄ΠΎΡΡΠ΅ΡΠΎΠ½-ΡΠΈΠ½ΡΠ°Π·Ρ. ΠΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅Π½ΠΈΠ½Π° ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ, ΡΡΠΎΠ²Π΅Π½Ρ Π°Π»ΡΠ΄ΠΎΡΡΠ΅ΡΠΎΠ½Π° ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ, Π°Π½ΡΡΠΎΠΏΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ, Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² Π³Π΅Π½Π° Π°Π»ΡΠ΄ΠΎΡΡΠ΅ΡΠΎΠ½-ΡΠΈΠ½ΡΠ°Π·Ρ, Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»ΠΈΡΡ. ΠΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎ -344Π’-Π°Π»Π»Π΅Π»Ρ Π³Π΅Π½Π° Π°Π»ΡΠ΄ΠΎΡΡΠ΅ΡΠΎΠ½ΡΠΈΠ½ΡΠ°Π·Ρ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ
THE PREVENTION, DIAGNOSIS, AND TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCIES IN THE ADULT POPULATION OF RUSSIA AND IN PATIENTS WITH OSTEOPOROSIS (ACCORDING TO THE MATERIALS OF PREPARED CLINICAL RECOMMENDATIONS)
The paper presents data on the role of vitamin D and calcium in the function of many human organs and tissues.Β Lifestyle, dietary preferences, and insufficient physical activity contribute to the high prevalence of vitamin D and calciumΒ deficiencies in the adult population of Russia, causing different diseases and abnormalities. The authors haveΒ worked out recommendations for the preventive use of vitamin D and calcium in healthy population, give consumptionΒ rates for these substances, and describe the clinical and laboratory signs of vitamin D deficiency and indicationsΒ for screening. They also propose treatment regimens for vitamin D deficiency and depict the signs of intoxication inoverdose. Particular emphasis is laid on the place of vitamin D and calcium in the therapy of osteoporosis